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Abstract
Background Like other premalignant conditions that develop in the presence of chronic inflammation, the development and
progression of Barrett’s esophagus is associated with the development of an immune response, but how this immune
response is regulated is poorly understood. A comprehensive literature search failed to find any report of the presence of
dendritic cells in Barrett’s intestinal metaplasia and esophageal adenocarcinoma and this prompted our study.
Material and Methods We used immunohistochemical staining and electron microscopy to examine whether dendritic cells
are present in Barrett’s esophagus and esophageal adenocarcinoma. Immunohistochemical staining with CD83, a specific
marker for dendritic cells, was performed on paraffin-embedded sections of Barrett’s intestinal metaplasia (IM, n=12),
dysplasia (n=11) and adenocarcinoma (n=14).
Results CD83+ cells were identified in the lamina propria surrounding intestinal type glands in Barrett’s IM, dysplasia, and
cancer tissues. Computerized quantitative analysis showed that the numbers of dendritic cells were significantly higher in
cancer tissues. Double immunostaining with CD83, CD20, and CD3, and electron microscopy demonstrated that dendritic
cells are present in Barrett’s esophagus and form clusters with T cells and B cells directly within the lamina propria.
Conclusions These findings demonstrate that dendritic cells are present in Barrett’s tissues, with a significant increase in
density in adenocarcinoma compared to benign Barrett’s esophagus. Dendritic cells may have a role in the pathogenesis and
immunotherapy treatment of Barrett’s esophagus and adenocarcinoma.
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Introduction
Barrett’s esophagus is the condition in which the normal
squamous lining of the distal esophagus is replaced by a
metaplastic columnar epithelium containing goblet cells
(intestinal metaplasia, IM) in response to chronic severe
gastro-esophageal reflux.1–4 It is a multistage disease in
which IM progresses in a minority of cases to low-grade
dysplasia (LGD), high-grade dysplasia (HGD), and even-
tually esophageal adenocarcinoma.1–4 Despite significant
improvements in medical and surgical oncology treatments,
survival outcomes for patients with this cancer remain poor,
with community 5-year survival rates less than 20%.5 For
reasons that are not fully known, but probably include an
increase in Barrett’s esophagus6 and a causative association
with the increased prevalence of overweight and obesity,7,8
there has been a dramatic increase in the incidence of
esophageal adenocarcinoma in many Western countries.9,10
In the United States, for example, the rate of increase in
esophageal adenocarcinoma incidence exceeds that of any
other major cancer in the past 25 years, with a more than
600% increase.9
Components of the gastroesophageal refluxate are
thought to include the injurious stimuli responsible for the
accumulated genetic abnormalities present in Barrett’s
mucosa.2,3,11 It has been reported that premalignant
conditions that develop in the presence of chronic inflam-
mation are often associated with the development of an
immune response during the progression of the disease.
How the immune responses are regulated is poorly
understood,12–15 but a marked increase has been reported
in numbers of T cells and B cells in Barrett’s oesophagus.16
Antigen-specific T-cell activation is known to critically
depend on the interactions of T-cell receptors with antigens
presented by specialized antigen-presenting cells17 includ-
ing dendritic cells, a unique family of specialized antigen-
presenting cells.18–24
Initially described in the skin by Langerhans in 1868,
dendritic cells were identified as antigen-presenting cells in
1973 by the pioneering work of Steinman and Cohn.25
Although macrophages, monocytes and B cells have
traditionally been viewed as antigen-presenting cells,
dendritic cells, which express high levels of both class I
and class II major histocompatibility complex (MHC)
molecules and co-stimulatory molecules, are now consid-
ered the principal initiators of immune responses by virtue
of their unique ability to activate naive T cells.18–24
Dendritic cells arise from a common CD34+ progenitor in
the bone marrow and their development involves three
stages, for which the terms precursor, immature, and
mature, are commonly used.18–24 Dendritic cell precursors
exit the bone marrow and circulate via the bloodstream to
reach their target tissues, taking up residence at sites of
potential antigen entry.18–24 In this stage, dendritic cells are
present in essentially all tissues but are mostly concentrated
along epithelial and body cavity surfaces. In these loca-
tions, dendritic cells continuously and efficiently sample the
antigenic content of their microenvironment by phagocyto-
sis or endocytosis.18–24 Antigen is then processed intracel-
lularly, being degraded into short peptides that are loaded
onto nascent MHC for subsequent display on the cell
surface. Cells with these properties are termed immature or
processing dendritic cells as, in this stage, they are yet
unable to stimulate T cells.18–24 Processing dendritic cells
usually exit the nonlymphoid tissues and migrate via the
afferent lymph into the lymphoid tissues such as the spleen
and lymph nodes, where dendritic cells then complete their
maturation.18–24 Maturation of dendritic cells involves the
down-regulation of endocytotic activity and the up-
regulation of adhesion molecules and antigen-presenting
molecules. Once activated, dendritic cells migrate to the
lymphoid tissues where they interact with T cells and B cells
to initiate and shape the adaptive immune response.18–24
The involvement of dendritic cells in tumorigenesis has
clinical importance. The infiltration of dendritic cells into
some primary tumor types has been found to be associated
with significantly improved patient survival and a reduced
incidence of recurrent disease, indicating an important
immune-regulating role for dendritic cells in the local
tumor environment.26–35 Furthermore, dendritic cells can be
used to manipulate immune responses, including those for
cancer immunotherapy.
We undertook this study after a comprehensive literature
search failed to find any report of the presence of dendritic
cells in Barrett’s intestinal metaplasia and esophageal
adenocarcinoma.
We now report that dendritic cells are present in Barrett’s
metaplasia, dysplasia, and adenocarcinoma, and speculate
that dendritic cell-dependent lymphocyte activation might
occur in this disease.
Material and Methods
Tissue Specimens and Routine Histology
Endoscopic biopsy or operative surgical specimens were
obtained from 37 patients with Barrett’s esophagus or
esophageal adenocarcinoma. Barrett’s esophagus was diag-
nosed by the presence of a macroscopic area of columnar-
lined esophagus as well as microscopic intestinal metaplasia
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with goblet cells. Material was collected in accordance with
the principles outlined in the Declaration of Helsinki after
approved by the Institutional Review Board of St. Vincent’s
Hospital, Sydney, and informed consent was obtained from
each patient. Tissue specimens were processed by standard
formalin fixation and paraffin embedding. Paraffin sections
cut at 5–7 μm thickness were stained with Mayer’s
hematoxylin and eosin. After review by an experienced
gastrointestinal pathologist, the specimens were classified as
Barrett’s intestinal metaplasia without dysplasia (IM, n=12),
dysplasia (n=11), and adenocarcinoma (n=14).
Immunohistochemistry and Quantitative Analysis
Single and double immunostaining for CD83, an inducible
glycoprotein belonging to the immunoglobulin superfamily,36
was performed. CD83 is important in T-cell immunity
mediated by dendritic cells and is the most specific dendritic
cell marker.36–40 For single immunostaining, after elimina-
tion of endogenous peroxidase activity by 3% H2O2, sections
were preincubated with normal non-immune serum and then
tested by avidin–biotin complex using a standard ABC
immunoperoxidase method.41 Anti-CD83 (Immunotech; cat
no IM-2069) was used in a 1:50 dilution. After washing in
Tris–phosphate buffered saline (TPBS), pH 7.6, the sections
were incubated with a biotin-labeled secondary antibody,
followed by a treatment with avidin–biotin complex (ELITE
ABC, VECTOR PK61000). After washing in TPBS, brown
staining was produced by 5-min treatment with 3,3’-
diaminobenzidine (DAB). All the incubations were complet-
ed at room temperature. Archival lymph node sections were
used for positive controls. For negative controls, the first
antibodies were omitted or the sections were treated with an
immunoglobulin fraction of non-immune goat serum as a
substitute for the primary antibody. None of the negative
control sections showed positive immune staining. Counter-
staining was performed with Mayer’s hematoxylin.
A computerized quantitative analysis of CD83 expression
was carried out at ×400 magnification using the Image-Pro
Plus image analysis program (Media Cybernetics, Bethesda,
MD.). CD83 expression was measured in each section in at
least seven randomly selected microscopic fields containing
both CD83+ cells and epithelial glands. Statistical comparison
of expression, measured in pixels per standard microscopic
field (0.04 mm2), was performed by t test using Prism® 4
(GraphPad Software, San Diego, CA.).
Double immunostaining with CD83/CD3 and CD83/CD20
was used to analyze the possible co-localization of dendritic
Figure 1 Typical patterns of
distribution of CD83+dendritic
cells in biopsy samples of
Barrett’s metaplasia
(A–G). A Single ABC immu-
nostaining showing the presence
of dendritic cells (brown) in the
lamina propria surrounding
metaplastic glands. B–G Double
immunostained sections show-
ing the distribution of CD83+
dendritic cells and their associa-
tion with lymphocytes. CD83
antigen was visualized using
ABC immunoperoxidase reac-
tion (brown reaction product)
while CD20+ cells (B, E, G)
and CD3+ cells (C, D, F) were
visualized using a Fast red
substrate kit (rose reaction
product). Counterstaining with
Mayer’s hematoxylin. In
(E–G), note dendritic cells
clustering with lymphocytes.
Bars = 100 μm (A–D) and
50 μm (E–G).
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cells with lymphocytes, using previously reported methods.37
In brief, after visualization of CD83 with the ABC substrate
kit, sections were washed with 0.1M glycine-hydrochloric
acid buffer, pH 2.2, and then incubated with anti-CD3
(Dako; cat no A0452; 1:100 dilution) or anti-CD20 antibody
(Beckman-Coulter; cat no 1925; 1:50 dilution). After rinsing
in TPBS, the sections were incubated with biotinylated
secondary antibody and then with alkaline phosphatase-
conjugated streptavidin (Dako) or with avidin–biotin
complex (Dako). A combination of the peroxidase–
anti-peroxidase (PAP) and alkaline phosphatase–anti-alkaline
phosphatase (APAAP) techniques, with antigen visualization
with DAB or Fast Red, was also used. Controls were as for
single immunostaining.
Electron Microscopy
Fresh endoscopic biopsy specimens were fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4),
routinely processed and embedded in Spurr resin. Ultrathin
sections were stained with uranyl acetate and lead citrate
and examined with the aid of a Morgagni 268D electron
microscope. The electron microscopic identification of
dendritic cells was carried out according to their distinctive
ultrastructural features, which include the tubulovesicular
system and atypical granules as previously used.19, 42
Results
CD83 expression was identified in all 12 specimens with
Barrett’s IM without dysplasia. The numbers of CD83+
dendritic cells varied markedly in different specimens and
the cells were irregularly distributed throughout the lamina
propria (Fig. 1A). The intensity of CD83 immunopositivity
in individual cells varied notably as well, but in all
specimens, dendritic cells located in close proximity to
intestinal glands showed a lower intensity of immunoposi-
tivity than those located at a distance in areas of the lamina
propria enriched by capillary networks. Double immu-
nostaining utilizing combinations of anti-CD83, anti-CD20,
and anti-CD3 antibodies revealed that all specimens
contained various numbers of B cells (CD20+) and T cells
(CD3+) and that dendritic cells, T- cells, and B-cells
frequently formed clusters within the lamina propria
(Fig. 1B–G).
CD83+ cells were present between dysplastic glands in
all Barrett’s dysplasia tissue specimens, often with a patchy
distribution in the lamina propria (Fig. 2A,B) due to
frequent clustering of dendritic cells (Fig. 2C). Direct
contacts between dendritic cells and lymphocytes, includ-
ing T and B cells, were also identified (Fig. 2C–E). When
CD83+ dendritic cells were detected within inflammatory
cell infiltrates in the lamina propria, each individual
Figure 2 CD83+ dendritic cells
in biopsy samples containing
dysplastic changes in special-
ized intestinal type mucosa of
Barrett’s esophagus (A–F).
CD83 antigen was visualized
using ABC immunoperoxidase
reaction (brown reaction
product) while CD20+ cells
(A, E, F) and CD3+ cells
(B, C, D) were visualized using
a Fast red substrate kit (rose
reaction product). Counterstain-
ing with Mayer’s hematoxylin.
In (C), note dendritic cells
clustering with each other while
in (D, E), close apposition
between dendritic cells and
lymphocytes is evident. F Asso-
ciation of dendritic cells with
lymphocytes within an immune-
inflammatory infiltrate in the
lamina propria. Bars=100 μm
(A, B) and 50 μm (C, F) and
25 μm (D, E).
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dendritic cell seemed to cluster with several lymphocytes
(Fig. 2F).
CD83+ dendritic cells were detected in all esophageal
adenocarcinoma specimens. Similar to the pattern seen in the
Barrett’s dysplasia tissues, dendritic cells were distributed
mosaically in clusters between distorted glands (Fig. 3A–E).
Double immunostaining demonstrated direct contacts be-
tween dendritic cells and T and B cells in all specimens
studied. Notably, contacts between CD83+ dendritic cells
and lymphocytes were regularly seen in close proximity to
capillaries (Fig. 3F) and dendritic cells were frequently
observed within the lumen of capillaries forming networks
within the lamina propria (Fig. 3G).
There was no significant difference between the mean
CD83 expression in specimens of Barrett’s IM (599±145)
compared to Barrett’s dysplasia tissues (730±167) on the
computerized analysis (Fig. 4A). However, CD83 expres-
sion was significantly higher in adenocarcinoma specimens
(1235±139) compared to either IM or dysplasia tissues
(Fig. 4A). Figure 4 also shows the significantly higher
CD83 expression in adenocarcinoma compared to non-
adenocarcinoma Barrett’s tissues (1235±139 vs 662+109;
p=0.0026, all Student’s t test).
The presence of dendritic cells was investigated further
using electron microscopy. Cells with the typical appearance
of dendritic cells in other tissues19,42 were readily identified.
The direct contacts between esophageal dendritic cells and
lymphocyte-like cells as well as between dendritic cells
and plasma cells were also detected (Figs. 5A–F, 6A–C. and
7A–D). Similar to dendritic cells elsewhere, dendritic cells in
the esophagus were characterized by a cytoplasm of low
electron density, which contained a tubulovesicular system
Figure 3 Patterns of distribu-
tion of CD83+ dendritic cells
and their association with
lymphocytes in esophageal
adenocarcinoma tissue speci-
mens (A–G). CD83 antigen
was visualized using ABC
immunoperoxidase reaction
(brown reaction product) while
CD3+ cells (A–D, F) and CD20
+ cells (E) were visualized using
a Fast red substrate kit (rose
reaction product). Counterstain-
ing with Mayer’s hematoxylin.
(C) is a detail of (A). In (F),
note a contact of a dendritic cell
with a lymphocyte in close
proximity to a capillary. G Low
magnification image showing
the presence of dendritic cells
within lumens of capillaries
forming a network in an
adenocarcinoma tissue speci-
men; dendritic cells are also
seen around capillaries in the
lamina propria. Bars=150 μm
(A, G) and 100 μm (B), 50 μm
(D, F) 25 μm (E).
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unique to cells of the dendritic cell family (Figs. 5D, 6A–C,
7B,D). Atypical granules were present in some esophageal
dendritic cells (Figs. 6A,B and 7A,B), but their cytoplasm
lacked liposomes, rest bodies, or other organelles excluding
the Golgi complex (Figs. 5A–F, 6A–C, and 7A–D). As with
other dendritic cells, esophageal dendritic cells possessed
long cell processes, the continuity of which with the
dendritic cell body could be established in serial ultrathin
sections (Figs. 6B and 7B). The cytoplasmic content of
dendritic cell processes was limited either by granular and
agranular material of medium and low electron density,
respectively (Fig. 1B,E), or cisterns of the tubulovesicular
system had developed in the cell processes (Figs. 6A,B and
7B). Through multiple cell processes, dendritic cells con-
tacted T cell like cells (Fig. 1A–D) and plasma cells
(Fig. 5E–F) or, alternatively, close apposition of the cell
bodies of dendritic cells and lymphocytes was observed
(Figs. 6A and 7A).
Histologically normal stratified squamous epithelium
was present in some sections. There were only very rare
CD83+ dendritic cells, and no glands, in the lamina propria
underlying the normal squamous esophagus areas. Dendritic
cells had a similar appearance in normal esophagus and
Barrett’s diseases.
Discussion
This study demonstrates, by both immunohistochemistry
and electron microscopy, that dendritic cells reside in
Barrett’s esophagus and esophageal adenocarcinoma. The
certainty of this finding is supported by the studies36–40
reporting that CD83 is a specific marker for the identifica-
tion of dendritic cells, by the typical dendritic cell
appearance of the CD83+ cells found in Barrett’s tissues,
and, importantly, by the demonstration of the presence of
cells with structural features unique to the dendritic cell
family (tubulovesicular system and atypical granules) by
electron microscopy.
The unambiguous identification of dendritic cells is
essential because, to our knowledge, this is the first report
of the presence of dendritic cells in Barrett’s esophagus and
esophageal adenocarcinoma. The novelty of this report
is somewhat surprising in view of the interest in dendritic
cell immunotherapy for cancers, including esophageal
adenocarcinoma,43 and indicates that there is a pressing
need for further studies investigating the regulation of the
immune response in this disease.
According to the concept of immune surveillance, the
immune system is able to recognize and destroy a clone of
transformed cells before the clone becomes cancer.44
However, evidence from experimental and clinical obser-
vations shows that the immune system does not behave in
this way for many tumor types.44 Most tumor antigens are
weakly immunogenic and the immune functions, such as
the antigen-specific T-cell response initiated by professional
antigen-presenting cells, and immune regulation mediated
by regulatory cells often fail to operate adequately and thus
fail to prevent tumor growth.44–46 The importance of
dendritic cells in immune surveillance suggests that
infiltration of dendritic cells into tumors should have
prognostic significance,44–46 but this has not been a
consistent finding. An increased infiltration of dendritic
cells into esophageal squamous cell carcinoma and hepato-
cellular carcinoma is associated with good prognosis for
patients with such cancers,47–49 but there was no significant
association with prognosis in two studies of patients with
renal cell carcinoma, for example.50–52 As an explanation
for these variable findings, Mailliard et al.53 suggest that
Figure 4 Expression of CD83 antigen in specialized intestinal type
mucosa of Barrett’s esophagus without dysplasia (BE), dysplasia (D)
and adenocarcinoma (AC) evaluated as a number of pixel per standard
field using a computerized quantitative analysis (A) (see “Material and
methods” section). In (B), the expression of CD83 antigen in
specimens without adenocarcinoma (BE+D) compared with that in
adenocarcinoma specimens (AC).
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infiltrating dendritic cells might promote T-cell survival or
death, depending on their maturation stage and function.
We found significantly increased numbers of dendritic
cells in adenocarcinoma compared to benign Barrett’s
tissues. Indeed, the density of dendritic cells in the cancer
sections studied is among the highest, and perhaps the
highest reported for any non-cultured tissue.19 This de-
scriptive study does not address whether dendritic cells may
have a mechanistic role in the development and progression
of Barrett’s disease, but an involvement in local processes
associated with the development of adenocarcinoma in the
columnar epithelium is at least suggested. One mechanism
for dendritic cell involvement is that, although the numbers
of dendritic cells are increased, those residing in cancer
tissues can be defective. Such a possibility is in agreement
with the view that the defect of dendritic cells is one of the
important factors leading to the immune escape of tumor
growth.54,55 A consequence of the maturation of defective
dendritic cells can be a decrease in functionally competent
dendritic cells.54,55 Increased numbers of functionally
incompetent dendritic cells can induce the tolerance of T
cells, resulting in the tumor escaping from the surveillance of
the immune system.54,55 In renal cell carcinoma and prostate
cancer, infiltrated dendritic cells have lower allostimulatory
activity, while dendritic cells in the peripheral blood of
patients with breast cancer express lower levels of both
MHC II and co-stimulatory molecules.54,55 Almand et al.55
reported that despite that the increase in the numbers of
dendritic cells in lymph nodes and peripheral blood, their
ability to induce antigen-specific proliferation of autologous
T cells is significantly decreased.
The present immunohistochemical analysis revealed that
dendritic cells frequently contact both T cells and B cells in
Barrett’s esophagus and adenocarcinoma, and the electron
microscopic analysis showed that dendritic cells form direct
contacts with T cells through their long cellular processes.
As found in other tissues,19,42,56 the tubulovesicular system
in the dendritic cell processes that contact T cells is highly
hypertrophied, indicating dendritic cell activation. Although
not the focus of this study, similar to the report by Moons
et al.,16 we found a large number of plasma cells in
Barrett’s esophagus, indicating that a significant humoral
Figure 5 Electron micrographs
showing close apposition be-
tween dendritic cells and T cells
(A–D) as well as between a
dendritic cell process and a
plasma cell (E–F). (B) is a detail
of (A); (D) is a detail of (C);
(F) is a detail of (E). In (B, D,
and F), dendritic cells are
marked by stars. Bars=15 μm
(A), 4 μm (C), and 20 μm (E).
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immune response is occurring locally within the lamina
propria. Plasma cells with highly developed rough endo-
plasmic reticulum were seen in direct contact with dendritic
cells, suggesting a role for dendritic cells in the regulation
of immune reactions in esophageal pathology. Dendritic
cells were found around and within capillaries in the lamina
propria, further suggesting that esophageal dendritic cells
might also migrate in the immune organs by means of the
classical dendritic cell pathway.18–24
The identification of dendritic cells in Barrett’s esopha-
gus and esophageal adenocarcinoma has potential clinical
importance. The remarkable ability of dendritic cells to
elicit or diminish immune responses and the availability of
sophisticated dendritic cell culture systems have stimulated
the use of dendritic cells in cancer immunotherapy.18–24,57
Recent achievements in loading dendritic cells with
appropriate antigens have made it possible to produce in
vitro dendritic cells with desirable properties.57 Remarkable
progress in the field of cellular vaccination has been
achieved by means of genetic engineering of tolerogenic
dendritic cells.57 The very high density of dendritic cells in
esophageal adenocarcinoma in this study supports efforts to
develop dendritic cell immunotherapy for this cancer. The
findings also suggest further studies on the prognostic
significance of dendritic cell infiltration for progression to
more advanced Barrett’s stages and for the prognosis of
patients with Barrett’s cancer.
The scope of the present work was to investigate and
report the presence of dendritic cells in Barrett’s esophagus
and esophageal adenocarcinoma and the observation that
the number of dendritic cells in the cancers was signifi-
cantly higher than in non-malignant Barrett’s. Further
studies are required in order to examine the prognostic
value and functional characteristics of dendritic cells in this
disease.
Figure 7 Direct contacts between dendritic cells and plasma cells (A–
D). In (A–C), dendritic cells are marked by stars. Image (A) shows a
close apposition of dendritic cell body to the plasma cell plasmalemma
along a distance exceeding 3 μm while image (B) shows a contact of a
dendritic cell process with the plasma cell body. In (B), note the
presence of well-developed cisterns of the tubulovesicular system in a
dendritic cell process while in (A), note the presence of atypical
granules in the cytoplasm of the dendritic cell. C, D A direct contact
between a dendritic cell microvillus and a short process of a plasma
cell. (D) is a detail of (C). Bars=3 μm (A, C) and 2 μm (B).
Figure 6 A group of dendritic cells (A) exhibiting highly hypertro-
phied tubulovesicular system in their cellular processes (A, B) and in
the perinuclear cytoplasm (A, C). In (A), dendritic cells are marked by
stars. An esophageal adenocarcinoma specimen. Bar=6 μm.
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